KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Asset Writedowns and Impairment (2020 - 2025)

Biogen (BIIB) has 10 years of Asset Writedowns and Impairment data on record, last reported at $4.4 million in Q4 2025.

  • For Q4 2025, Asset Writedowns and Impairment fell 64.8% year-over-year to $4.4 million; the TTM value through Dec 2025 reached $7.9 million, down 86.88%, while the annual FY2025 figure was $7.9 million, 86.88% down from the prior year.
  • Asset Writedowns and Impairment reached $4.4 million in Q4 2025 per BIIB's latest filing, up from -$7.3 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $275.0 million in Q1 2022 and bottomed at -$36.8 million in Q3 2023.
  • Average Asset Writedowns and Impairment over 5 years is $62.6 million, with a median of $17.4 million recorded in 2023.
  • Peak YoY movement for Asset Writedowns and Impairment: soared 7738.89% in 2022, then crashed 330.0% in 2023.
  • A 5-year view of Asset Writedowns and Impairment shows it stood at $120.0 million in 2021, then soared by 129.17% to $275.0 million in 2022, then tumbled by 54.76% to $124.4 million in 2023, then crashed by 89.95% to $12.5 million in 2024, then plummeted by 64.8% to $4.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Asset Writedowns and Impairment were $4.4 million in Q4 2025, -$7.3 million in Q3 2025, and $3.5 million in Q2 2025.